Studies have reported conflicting findings regarding the role of VEGF in the clinicopathology of ESCC patients [8–10], possibly because different genetic variants combine with abnormal expression of VEGF to exert particular effects on different tumor cells [11]. The gene discussed is VEGFA; the disease is neoplasm.